<DOC>
	<DOCNO>NCT01254448</DOCNO>
	<brief_summary>This Phase 1 study examine safety , tolerability pharmacokinetics TC-5619 elderly subject without Alzheimer 's disease . Group 1 include elderly subject Alzheimer 's disease receive TC-5619 placebo 28 day evaluate safety tolerability . Group 2 include healthy elderly subject dose escalation design receive TC-5619 placebo 10 day evaluate safety , tolerability pharmacokinetics .</brief_summary>
	<brief_title>Multiple Ascending Dose Study TC-5619 Healthy Elderly Subjects Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria ( Groups 1 &amp; 2 ) : Normal body mass index ( BMI ) Nonsmoking minimum 3 month Subjects must reasonably good health , base medical history , physical examination , vital sign , ECG . Group 1 Only : Subjects Mini Mental State Examination score 1222 , inclusive . Diagnosis probable Alzheimer 's Disease accord National Institute Neurological Communicative Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria Subjects must reliable caregiver . Exclusion Criteria ( Groups 1 &amp; 2 ) : Subjects clinically significant heart disease , pulmonary disease , diabetes , neurologic psychiatric disease ( Group 1 subject must Alzheimer 's Disease ) , illness could interfere interpretation study result . Subjects past current history seizure participate . Current use donepezil , rivastigmine galantamine .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>